title: Breast cancer: are imaging studies cost effective following breast cancer and adjuvant therapy?
authors.affiliation: Fairgrounds Medical Center, Allentown, PA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Prager
authors.forename: S
authors.initials: S
authors.lastname: Grundfest-Broniatowski
authors.forename: H J
authors.initials: HJ
authors.lastname: Lerner
authors.forename: R G
authors.initials: RG
authors.lastname: Margolese
authors.forename: N
authors.initials: N
authors.lastname: Dimitrov
authors.forename: P
authors.initials: P
authors.lastname: Silverman
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000517:prevention & control / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000517:prevention & control / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003362:Cost-Benefit Analysis; D003520:Cyclophosphamide / Q000008:administration & dosage; D003952:Diagnostic Imaging / Q000191:economics*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D015412:Mastectomy, Segmental; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate